🇺🇸 Apixaban 2.5 mg in United States

30 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Dyspnoea — 5 reports (16.67%)
  2. Cardiac Arrest — 4 reports (13.33%)
  3. Abdominal Pain — 3 reports (10%)
  4. Fall — 3 reports (10%)
  5. Haemoglobin Decreased — 3 reports (10%)
  6. Nausea — 3 reports (10%)
  7. Unresponsive To Stimuli — 3 reports (10%)
  8. Asthenia — 2 reports (6.67%)
  9. Chest Pain — 2 reports (6.67%)
  10. Dizziness — 2 reports (6.67%)

Source database →

Apixaban 2.5 mg in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Apixaban 2.5 mg approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Apixaban 2.5 mg in United States?

Janssen Research & Development, LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.